Form 4: AnaptysBio Director Magda Marquet Acquires Stock Options and Restricted Stock Units

Director Magda Marquet reports acquisition of stock options and restricted stock units in AnaptysBio, Inc.

Summary

• On January 7, 2025, Magda Marquet, a director of AnaptysBio, Inc. (ANAB), reported the acquisition of stock options and restricted stock units (RSUs).
• Marquet acquired 16,510 stock options with an exercise price of $14.83.
• These options vest monthly, starting February 7, 2025, over a 12-month period, contingent upon continued service to the issuer, and expire on January 6, 2035.
• Additionally, Marquet acquired 6,030 RSUs, each representing the right to receive one share of AnaptysBio's common stock upon settlement.
• These RSUs vest 100% on the date of the Issuer's 2026 annual meeting of shareholders, subject to continued service.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock options and RSU grants to a director, which is a common practice. It doesn't necessarily indicate a strong positive or negative outlook.

Positives

• The acquisition of stock options and RSUs by a director signals confidence in the company's future performance.
• The vesting schedules for both the options and RSUs incentivize continued service and commitment to AnaptysBio.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge sentiment and potential future performance.

Stakeholder Impact

• Shareholders may view the acquisition of stock options and RSUs by a director as a positive sign, aligning the director's interests with the company's success.

Key Dates